MD Jorge Cortes (Assistant Professor of Medicine) , MD Hagop M. Kantarjian (Professor of Medicine, Chief) , MD Sergio Giralt (Assistant Professor of Medicine) , MD Moshe Talpaz (Professor of Medicine, Chairman)
{"title":"慢性骨髓性白血病的自然病史和分期","authors":"MD Jorge Cortes (Assistant Professor of Medicine) , MD Hagop M. Kantarjian (Professor of Medicine, Chief) , MD Sergio Giralt (Assistant Professor of Medicine) , MD Moshe Talpaz (Professor of Medicine, Chairman)","doi":"10.1016/S0950-3536(97)80007-8","DOIUrl":null,"url":null,"abstract":"<div><p>The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-α (IFN-α) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-α, but achieving a cytogenetic response with IFN-α is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.</p></div>","PeriodicalId":77029,"journal":{"name":"Bailliere's clinical haematology","volume":"10 2","pages":"Pages 277-290"},"PeriodicalIF":0.0000,"publicationDate":"1997-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3536(97)80007-8","citationCount":"23","resultStr":"{\"title\":\"6 Natural history and staging of chronic myelogenous leukaemia\",\"authors\":\"MD Jorge Cortes (Assistant Professor of Medicine) , MD Hagop M. Kantarjian (Professor of Medicine, Chief) , MD Sergio Giralt (Assistant Professor of Medicine) , MD Moshe Talpaz (Professor of Medicine, Chairman)\",\"doi\":\"10.1016/S0950-3536(97)80007-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-α (IFN-α) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-α, but achieving a cytogenetic response with IFN-α is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.</p></div>\",\"PeriodicalId\":77029,\"journal\":{\"name\":\"Bailliere's clinical haematology\",\"volume\":\"10 2\",\"pages\":\"Pages 277-290\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1997-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0950-3536(97)80007-8\",\"citationCount\":\"23\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bailliere's clinical haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0950353697800078\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical haematology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0950353697800078","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
6 Natural history and staging of chronic myelogenous leukaemia
The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-α (IFN-α) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-α, but achieving a cytogenetic response with IFN-α is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.